Selenium for Immune Function
Selenium's role in immune defense became unforgettable in 1995, when Melinda Beck and Orville Levander demonstrated something nobody had previously imagined possible — that nutritional deficiency in the host can drive a benign virus to mutate into a virulent one. Passaging a mild strain of Coxsackievirus B3 through selenium-deficient mice produced six specific point mutations in the viral genome that converted the virus into the cardiotoxic form responsible for Keshan disease, an endemic cardiomyopathy that had been killing children in selenium-poor regions of China for decades. Once it became virulent in the deficient host, the mutated virus retained its cardiotoxicity even when transmitted to selenium-replete mice. Selenium deficiency, in other words, was not just compromising the host's defense — it was actively selecting for more dangerous pathogens. This deep dive walks through that Keshan / Coxsackie story, the consequences for T-cell proliferation and macrophage function, the selenium-HIV CD4 relationship, the influenza-severity data, sepsis-IV selenium trials, and the unexpectedly important SELECT-trial high-grade-prostate-cancer signal that has reframed how clinicians think about supplementing selenium-replete adults.
Table of Contents
- The Keshan / Coxsackievirus B3 Story
- Viral Mutation Prevention as an Immune Function
- T-Cell Proliferation and Differentiation
- Macrophage and Natural Killer-Cell Function
- Selenium and Human Immunodeficiency Virus / CD4 Counts
- Selenium and Influenza Severity
- Sepsis Intravenous Selenium Trials
- The SELECT Trial Prostate-Cancer Signal
- Adult Clinical Applications
- Cautions and the Replete-Patient Problem
- Key Research Papers
- Connections
- Featured Videos
The Keshan / Coxsackievirus B3 Story
Keshan disease is an endemic dilated cardiomyopathy first described in 1935 in Keshan County, Heilongjiang Province in northeastern China. The disease appeared in spatially clustered seasonal outbreaks, predominantly affecting children and women of childbearing age, with mortality from acute or subacute heart failure reaching 30 to 50 percent of cases in the worst-affected villages. Chinese epidemiologists determined by the late 1970s that the disease occurred almost exclusively in a belt of selenium-deficient soil stretching from northeastern China through Tibet, and that prophylactic selenium supplementation (initially as sodium selenite tablets distributed by village health workers) dramatically reduced incidence. By the mid-1980s, mass selenium supplementation had largely eliminated new cases.
But selenium supplementation alone did not explain everything. Keshan disease had a striking seasonal and geographic clustering that pure nutritional deficiency could not account for — outbreaks occurred in waves that respected village boundaries and seasonal patterns more consistent with an infectious agent than a nutritional disease. The pieces came together in the 1990s, when Melinda Beck, Orville Levander, and colleagues published a remarkable series of experiments at the U.S. Department of Agriculture (USDA) and the University of North Carolina.
- Beck and Levander infected selenium-deficient mice and selenium-replete mice with a mild, non-cardiotoxic strain of Coxsackievirus B3 (CVB3/0). The selenium-replete mice cleared the virus without cardiac damage. The selenium-deficient mice developed myocarditis and inflammatory cardiac lesions identical to Keshan-disease histology.
- When they then passaged virus recovered from the selenium-deficient mice through fresh selenium-replete mice, the recipient mice also developed myocarditis — the virus had now acquired cardiotoxicity that persisted regardless of host selenium status.
- Sequencing the recovered virus revealed six specific point mutations in the CVB3 genome (changes at nucleotides 234, 788, 2271, 2438, 3324, and 7334) that were stably present in the now-virulent strain and absent from the original mild parental strain.
- The same passage-through-deficient-host pattern produced virulent variants from a mild strain of influenza A as well, suggesting the selection mechanism was not Coxsackievirus-specific.
This was a paradigm shift in microbiology and nutrition. The conventional understanding of nutritional immunology had been that micronutrient deficiency weakens the host's ability to fight an unchanging pathogen. Beck and Levander showed that micronutrient deficiency can also drive directional pathogen evolution — the deficient host is not just easier to infect, it is an incubator for the appearance of more virulent strains. The proposed mechanism: the increased oxidative stress in selenium-deficient host cells accelerates the mutation rate of RNA viruses (which already have error-prone polymerases), and the resulting mutational pressure preferentially selects for variants with enhanced replication or tissue tropism.
Viral Mutation Prevention as an Immune Function
The Beck-Levander findings have been replicated for several other RNA viruses and have implications well beyond Keshan disease.
- Influenza A – Subsequent work showed selenium-deficient mice infected with mild influenza A/Bangkok/1/79 strain produced virus with 29 stable point mutations not found in the parental strain, including mutations in the hemagglutinin (HA) and matrix (M) genes known to affect virulence and tropism.
- Human immunodeficiency virus (HIV) – In vitro work in human immunodeficiency virus-infected cell cultures shows that selenium supplementation (in the form of sodium selenite) suppresses human immunodeficiency virus replication and reduces the rate of accumulation of human immunodeficiency virus genome mutations, suggesting a similar mechanism may operate for retroviruses.
- Hepatitis C – Observational studies of hepatitis C virus patients in selenium-poor regions show higher rates of viral quasispecies diversity (a marker of mutation rate) than in selenium-replete populations.
- Hantavirus and other RNA virus zoonoses – Several emerging zoonotic outbreaks have been epidemiologically linked to selenium-deficient regions, and this is one of the proposed contributing factors.
The mechanistic explanation is that RNA viruses have intrinsically high error rates because their RNA-dependent RNA polymerases lack proofreading activity. The error rate per replication cycle is the multiplicative product of polymerase fidelity and the oxidative-stress level of the host cell. Selenium-dependent glutathione peroxidase (GPx) and thioredoxin reductase (TrxR) enzymes reduce host-cell oxidative stress, lowering the spontaneous mutation rate of the replicating viral genome. Under selenium deficiency, the elevated oxidative stress acts as a mutagen on viral RNA, and the natural-selection bottleneck that follows favors variants with enhanced fitness in the deficient-host environment — which often correlates with virulence.
T-Cell Proliferation and Differentiation
Beyond the unusual host-pathogen-mutation effect, selenium plays a more conventional role in adaptive immunity at the level of T-cell biology.
- T-cell receptor (TCR) signaling – TCR engagement triggers a signaling cascade that includes oxidation of the protein tyrosine phosphatase SHP-2, which acts as a redox-sensitive brake on downstream signaling. Selenoenzyme activity calibrates this redox brake; selenium-deficient T cells show abnormal TCR signaling and impaired clonal expansion.
- Clonal proliferation – The thioredoxin-reductase / ribonucleotide-reductase pathway described on the Antioxidant Defense page is rate-limiting for the deoxyribonucleotide pool needed to support the rapid DNA replication of clonally expanding T cells. Selenium-deficient T cells proliferate more slowly in response to antigen stimulation.
- Th1 / Th2 / Th17 / Treg balance – Selenium supplementation in human trials has shifted the cytokine profile toward Th1 dominance (IFN-gamma, IL-2) with modest reduction in Th2 cytokines. There is less Th17/Treg literature for selenium than there is for vitamin D or retinoic acid, but observational data suggest similar redox-dependent effects.
- Memory T-cell generation – The differentiation of effector T cells into long-lived memory T cells is metabolically demanding and depends on oxidative phosphorylation, mitochondrial biogenesis, and tight redox regulation — all processes dependent on selenoprotein-mediated antioxidant defense, particularly mitochondrial thioredoxin reductase 2 (TrxR2).
- Antibody responses – Selenium-supplemented adults given seasonal influenza vaccine in several small trials showed modest improvements in seroconversion rates and antibody titers, particularly in elderly populations with marginal baseline selenium status.
Macrophage and Natural Killer-Cell Function
The innate immune system depends on selenium-containing enzymes for both effector function and self-protection.
- Macrophage respiratory burst – Activated macrophages and neutrophils generate massive amounts of superoxide and hydrogen peroxide via reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase to kill engulfed pathogens. Without adequate GPx activity to confine that oxidative attack to the phagolysosome, the cell damages itself. Selenium-deficient macrophages show impaired phagocytic killing of intracellular bacteria (Listeria, Salmonella, Mycobacterium tuberculosis) and shorter functional lifespan.
- M1 / M2 polarization – Selenium promotes the M1 (classically activated, pro-inflammatory, anti-tumor) phenotype over the M2 (alternatively activated, tissue-repair, tumor-promoting) phenotype. This is part of the rationale for selenium's anti-tumor effects on the Cancer Prevention page.
- Natural killer (NK) cell cytotoxicity – Multiple clinical studies have documented that selenium supplementation (typically 200 mcg/day for 8 to 16 weeks) increases natural killer cell cytotoxic activity in selenium-marginal subjects. The mechanism involves both improved redox protection of natural killer cells during cytotoxic effector function and enhanced expression of natural killer-activating receptors.
- Neutrophil function – Selenium-deficient neutrophils show reduced superoxide generation, impaired chemotaxis, and reduced lifespan. In humans receiving total parenteral nutrition without selenium, neutropenia and impaired neutrophil function have been documented and reverse with selenium repletion.
- Dendritic cell maturation – Less well-characterized than the T-cell and macrophage effects, but selenium-deficient dendritic cells show impaired antigen-presenting function and reduced expression of co-stimulatory molecules CD80 and CD86.
Selenium and Human Immunodeficiency Virus / CD4 Counts
Human immunodeficiency virus infection is associated with progressive depletion of plasma selenium, which falls in proportion to CD4 count and serves as an independent predictor of mortality in untreated human immunodeficiency virus patients. The relationship is so robust that low plasma selenium was incorporated into pre-antiretroviral-therapy (ART) era human immunodeficiency virus staging tools as a mortality risk marker.
- Baum et al. 1997 – In 125 human immunodeficiency virus-positive drug users in Miami followed for 3.5 years (21 died of HIV-related causes), selenium deficiency was associated with a much higher risk of HIV-related death (relative risk 19.9), and still a roughly 11-fold higher risk (relative risk 10.8) when CD4 counts and other nutrient deficiencies were considered jointly; zidovudine treatment was not associated with survival.
- Hurwitz et al. 2007 (Miami human immunodeficiency virus trial) – 262 human immunodeficiency virus-positive adults began a 9-month randomized trial of high-selenium yeast (200 mcg/day) vs placebo, and 174 completed it. In the intention-to-treat analysis, a greater rise in serum selenium predicted lower viral load, which in turn predicted higher CD4 counts. Selenium-treated subjects whose serum selenium rose by more than 26.1 mcg/L (who also took their capsules more reliably) showed no change in viral load (−0.04 log) and a CD4 rise of 27.9 cells/µL, while those with smaller rises showed a viral-load increase of 0.29 log and a CD4 fall of 25.8 cells/µL.
- Kupka et al. (Tanzania pregnancy trial) – In 915 human immunodeficiency virus-positive pregnant women in Tanzania, 200 mcg/day selenomethionine did not change hemoglobin but cut the risk of diarrhea by 40% (relative risk 0.60; Kupka et al. 2009); the trial did not affect mother-to-child human immunodeficiency virus transmission rates.
- ART-era updates – In patients on effective antiretroviral therapy with suppressed viral loads, the selenium-CD4 relationship is much weaker, and selenium supplementation in well-managed ART-replete patients does not produce the dramatic effects seen in untreated patients in the 1990s. The mechanism appears to be ART itself: by suppressing viral replication, ART reduces the oxidative stress that drives selenium consumption.
The human immunodeficiency virus-selenium story is not a straightforward "selenium fights human immunodeficiency virus" narrative. Instead, it is one of selenium status determining how rapidly an untreated human immunodeficiency virus infection progresses, mediated by both direct antiviral effects (suppression of viral mutation as discussed above) and indirect effects on T-cell preservation. In the era of universal antiretroviral therapy, the practical relevance is mostly to ensure adequate selenium status as part of nutritional support, not to use high-dose selenium as primary therapy.
Selenium and Influenza Severity
The Beck-Levander finding that selenium deficiency drives influenza A mutation has been complemented by observational and intervention data on influenza severity and vaccine response.
- Beck et al. influenza-mouse model – Selenium-deficient mice infected with mild influenza A developed more severe lung pathology, prolonged viral shedding, and higher mortality than selenium-replete controls. The mechanism involved both impaired host clearance and selection for virulent viral variants as described above.
- Broome et al. UK trial 2004 – Twenty-two otherwise healthy UK adults with relatively low plasma selenium were randomized to 50 or 100 mcg/day selenium (as sodium selenite) or placebo for 15 weeks; all were given live attenuated oral polio vaccine after 6 weeks as an immune readout. Selenium increased interferon-gamma and other cytokines, brought an earlier peak in T-cell proliferation and more T helper cells, and led to faster clearance of the vaccine virus from stool with fewer viral mutations; antibody responses were unaffected. The authors concluded that even the extra 100 mcg/day may be insufficient to support optimal function.
- Vaccine antibody response – Several small trials have documented that selenium supplementation modestly improves seasonal-flu vaccine seroconversion in selenium-marginal elderly subjects, though the effect size is smaller than that of optimizing vitamin D status.
- Geographic correlations – Pre-pandemic regional flu mortality data show modest correlations between population-level selenium status and severity of seasonal flu outbreaks, though this is confounded by many other factors.
The practical takeaway is similar to the human immunodeficiency virus story: ensuring adequate selenium status is part of immune-system optimization, but supraphysiologic dosing in already-replete adults does not produce additive benefit for flu prevention.
Sepsis Intravenous Selenium Trials
Severe sepsis and septic shock are associated with rapid depletion of plasma selenium and selenoprotein activity, and selenium intravenous (IV) supplementation has been investigated as adjunct therapy in critical-care medicine for two decades.
- Angstwurm et al. 2007 (German Selenium in Intensive Care Trial) – Multicenter trial of 249 intensive care unit (ICU) patients with severe sepsis randomized to high-dose intravenous sodium selenite (1000 mcg loading dose followed by 1000 mcg/day for 14 days) vs placebo. In the intention-to-treat analysis of 238 patients (11 were excluded), 28-day mortality was 39.7% with selenium vs 50.0% with placebo (p = 0.109, not significant). After a further 49 patients were excluded for severe protocol violations, the per-protocol analysis showed 42.4% vs 56.7% (p = 0.049). The trial generated significant enthusiasm for high-dose intravenous selenium as sepsis adjunctive therapy.
- SISPCT trial (Bloos et al. 2016) – Larger and more rigorous 1089-patient trial of high-dose intravenous selenium (1000 mcg loading dose, then 1000 mcg/day until discharge from intensive care, for up to 21 days) plus or minus procalcitonin-guided antibiotic stewardship. Found no mortality benefit from selenium: 28-day mortality was 28.3% with selenium vs 25.5% with placebo (P = 0.30, not significant). The SISPCT result has substantially dampened enthusiasm for high-dose intravenous selenium in sepsis.
- REDOXS trial (Heyland et al. 2013) – A blinded 2-by-2 factorial trial of glutamine and antioxidants (including 500 mcg/day intravenous selenium) in 1,223 mechanically ventilated intensive care unit patients with multiorgan failure in 40 units in Canada, the United States and Europe. Antioxidants had no effect on 28-day mortality (30.8% vs 28.8% without antioxidants; P = 0.48) or on any other secondary end point. The higher death rate was linked to glutamine (28-day mortality 32.4% vs 27.2%; in-hospital and 6-month mortality significantly higher). The combination-therapy design makes it hard to isolate the selenium contribution.
- Umbrella review (Jaff et al. 2023) – Pooling 17 meta-analyses covering 24 randomized trials in critically ill adults, selenium was linked to fewer deaths (risk ratio 0.83) and less acute kidney failure (risk ratio 0.67), but the certainty of the evidence was low. No significant effect was found on infections, pneumonia, days on a ventilator, or length of intensive care or hospital stay.
- Current critical-care guidance – Major sepsis guidelines (Surviving Sepsis Campaign 2021) do not recommend routine high-dose intravenous selenium for sepsis. Where selenium intravenous is used at all, it is usually as part of a "standard intensive care unit micronutrient package" at maintenance doses (60 to 100 mcg/day) rather than as supraphysiologic adjunctive therapy.
The SELECT Trial Prostate-Cancer Signal
The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was launched in 2001 to confirm the apparent prostate-cancer protection seen in the earlier Nutritional Prevention of Cancer (NPC) trial. SELECT randomized 35,533 men aged 55 or older (50 or older for African American men) to one of four arms: selenium alone (200 mcg/day as selenomethionine), vitamin E alone (400 international units (IU)/day), both, or neither, with a planned follow-up of 7 to 12 years.
- Early termination 2008 – The trial was stopped early when interim analysis showed no benefit from either intervention and a non-significant trend toward harm. At that point (data to October 2008, median follow-up 5.46 years) the hazard ratios for prostate cancer against placebo were 1.13 for vitamin E alone (not statistically significant, P = .06), 1.04 for selenium alone and 1.05 for the combination.
- Extended follow-up findings – Subsequent analyses of the SELECT cohort with longer follow-up showed:
- With data to July 2011, the vitamin-E-only arm showed a statistically significant 17% increase in prostate cancer (hazard ratio 1.17) and the selenium-only arm a non-significant 9% increase (hazard ratio 1.09); the combination arm showed no significant difference (hazard ratio 1.05). In absolute terms, that was 1.6 extra prostate cancers per 1,000 person-years with vitamin E, 0.8 with selenium and 0.4 with both (Klein et al. 2011).
- In a 2014 case-cohort analysis using toenail selenium measured at entry (Kristal et al.), selenium supplementation (selenium-only and selenium-plus-vitamin-E arms combined) raised the risk of high-grade prostate cancer by 91% in men whose baseline selenium was already higher (60th percentile or above) — the most worrying single signal from any selenium chemoprevention trial.
- In men with lower baseline selenium (below the 60th percentile), supplementation had no effect.
- Interpretation – The most coherent reading is that selenium supplementation in already-replete adults does not help and may worsen high-grade prostate cancer risk, while the apparent benefit seen in NPC was largely driven by the subset of NPC participants who had low baseline selenium. The NPC and SELECT trials together support a U-shaped dose-response for selenium and prostate cancer: too little and too much both increase risk.
- Form vs dose argument – Some commentators have argued that the negative SELECT result reflects the use of pure selenomethionine (which loads non-specifically into the methionine pool) rather than the selenium-enriched yeast used in NPC (which delivers a mix of selenoamino acids including the methylselenocysteine that produces the chemopreventive methylselenol metabolite). Selenium-enriched broccoli or selenium yeast may yet be useful where selenomethionine is not. But this remains hypothesis, not evidence.
The SELECT prostate-cancer signal is the single most important reason that mainstream guidelines do not recommend selenium supplementation for cancer prevention in well-nourished populations. For adults who are not deficient, it also means the safety margin for high-dose selenium taken "for immunity" or any other reason is much narrower than it is for water-soluble vitamins.
Adult Clinical Applications
Synthesizing all of the above, the practical applications of selenium for immune function in adult patients in developed countries with adequate food supply are concentrated in specific clinical contexts:
- Documented deficiency – Plasma selenium below 70 to 80 ng/mL is commonly treated with repletion at 100 to 200 mcg/day as selenomethionine or selenized yeast, with recheck at 3 to 6 months; the targets used are 120 to 150 ng/mL plasma selenium or 70 to 90 mcg/g selenoprotein P (SELENOP).
- Malabsorption syndromes – Crohn's disease, ulcerative colitis, celiac disease, cystic fibrosis, and short-bowel syndrome routinely produce subclinical selenium deficiency, which is assessed and treated as part of micronutrient management.
- Bariatric surgery – Lifelong selenium repletion (100 to 200 mcg/day) is part of standard post-bariatric supplementation, especially after duodenal switch.
- Long-term parenteral nutrition – Total parenteral nutrition (TPN) formulations include selenium (typically 60 to 100 mcg/day intravenous); without it, the cardiomyopathy and skeletal myopathy of acquired selenium deficiency can develop.
- Hashimoto's thyroiditis with positive anti-thyroid peroxidase (anti-TPO) antibodies – See the Selenium and Thyroid Function page; 200 mcg/day selenomethionine for 6 to 12 months is the typical evidence-based regimen.
- Mild Graves' orbitopathy – Selenium 100 mcg twice daily for 6 months per the European Group on Graves' Orbitopathy (EUGOGO) trial protocol is the strongest guideline-endorsed use of selenium for any indication.
- Human immunodeficiency virus with marginal selenium status not on ART – Increasingly rare in developed-world settings, but still relevant in resource-limited settings; the Hurwitz Miami trial used 200 mcg/day of high-selenium yeast.
- Routine supplementation in selenium-replete adults – No benefit has been shown. In SELECT, 200 mcg/day raised high-grade prostate cancer risk by 91% in men whose selenium status was already higher (Kristal 2014).
Cautions and the Replete-Patient Problem
- Replete-patient SELECT signal – The single most important caution about adult selenium supplementation. In SELECT men whose baseline toenail selenium was already higher (60th percentile or above), 200 mcg/day selenomethionine was associated with a 91% increase in high-grade prostate cancer. The study authors concluded: “Men should avoid selenium or vitamin E supplementation at doses that exceed recommended dietary intakes.”
- Type 2 diabetes signal from NPC – Long-term follow-up of NPC trial participants showed a small but significant increase in incident type 2 diabetes in the 200 mcg/day selenium arm. The mechanism is incompletely understood but may involve selenoprotein effects on insulin signaling at supraphysiologic intakes.
- U-shaped relationship – Cancer, cardiovascular disease, and all-cause mortality data consistently show a U-shaped relationship with selenium status — below ~70 ng/mL plasma and above ~140 to 150 ng/mL plasma both confer increased risk. The narrow "sweet spot" between deficiency and supratherapeutic burden is roughly 90 to 140 ng/mL.
- Selenosis – Chronic intake above 400 mcg/day from supplements or accidental dietary overload (Brazil nuts) produces garlic breath, brittle nails, hair loss, peripheral neuropathy, and gastrointestinal (GI) distress. Severe cases require dose reduction or cessation; effects largely reverse over weeks to months.
- Tuberculosis – By analogy to vitamin A's mixed signal in pulmonary tuberculosis (TB), supraphysiologic selenium in active tuberculosis has not been shown beneficial and is not part of standard tuberculosis management. Selenium repletion in deficient tuberculosis patients is reasonable; supraphysiologic dosing is not.
- Drug interactions – May enhance anticoagulant effect; a 4-hour gap from levothyroxine is commonly described to avoid binding interference; possible interaction with cisplatin-based chemotherapy (selenium may protect tumor cells from chemotherapy-induced oxidative damage).
- Chronic kidney disease – Impaired SELENOP clearance can produce elevated plasma selenium in advanced chronic kidney disease (CKD), so supplements add to a level that may already be raised.
This content is provided for informational purposes only and does not constitute medical advice. The adult tolerable upper intake level for selenium is 400 mcg/day from all sources (Institute of Medicine, 2000). In SELECT, 200 mcg/day raised high-grade prostate cancer risk in men whose selenium was already higher; in the NPC trial, 200 mcg/day was linked to more type 2 diabetes; plasma selenium can already be raised in advanced kidney disease; and a handful of Brazil nuts can exceed the upper limit.
Key Research Papers
- Beck MA, Kolbeck PC, Rohr LH, et al. (1994). Benign human enterovirus becomes virulent in selenium-deficient mice. Journal of Medical Virology. — DOI: 10.1002/jmv.1890430213. — doi:10.1002/jmv.1890430213
- Beck MA, Shi Q, Morris VC, Levander OA (1995). Rapid genomic evolution of a non-virulent Coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nature Medicine. — DOI: 10.1038/nm0595-433. — doi:10.1038/nm0595-433
- Beck MA, Nelson HK, Shi Q, et al. (2001). Selenium deficiency increases the pathology of an influenza virus infection. FASEB Journal. — DOI: 10.1096/fj.00-0721fje. — doi:10.1096/fj.00-0721fje
- Levander OA, Beck MA (1997). Interacting nutritional and infectious etiologies of Keshan disease: insights from coxsackie virus B-induced myocarditis in mice deficient in selenium or vitamin E. Biological Trace Element Research. — DOI: 10.1007/bf02778980. — doi:10.1007/bf02778980
- Baum MK, Shor-Posner G, Lai S, et al. (1997). High risk of HIV-related mortality is associated with selenium deficiency. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 15(5):370–374. — DOI: 10.1097/00042560-199708150-00007. — doi:10.1097/00042560-199708150-00007
- Hurwitz BE, Klaus JR, Llabre MM, et al. (2007). Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine. — DOI: 10.1001/archinte.167.2.148. — doi:10.1001/archinte.167.2.148
- Broome CS, McArdle F, Kyle JA, et al. (2004). An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status. American Journal of Clinical Nutrition. — DOI: 10.1093/ajcn/80.1.154. — doi:10.1093/ajcn/80.1.154
- Angstwurm MWA, Engelmann L, Zimmermann T, et al. (2007). Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Critical Care Medicine. 35(1):118–126. — DOI: 10.1097/01.CCM.0000251124.83436.0E. — doi:10.1097/01.CCM.0000251124.83436.0E
- Bloos F, Trips E, Nierhaus A, et al. (2016). Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial (SISPCT). JAMA Internal Medicine. — DOI: 10.1001/jamainternmed.2016.2514. — doi:10.1001/jamainternmed.2016.2514
- Lippman SM, Klein EA, Goodman PJ, et al. (2009). Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. — DOI: 10.1001/jama.2008.864. — doi:10.1001/jama.2008.864
- Kristal AR, Darke AK, Morris JS, et al. (2014). Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute. — DOI: 10.1093/jnci/djt456. — doi:10.1093/jnci/djt456
- Klein EA, Thompson IM Jr, Tangen CM, et al. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. — DOI: 10.1001/jama.2011.1437. — doi:10.1001/jama.2011.1437
- Heyland D, Muscedere J, Wischmeyer PE, et al. (2013). A randomized trial of glutamine and antioxidants in critically ill patients. New England Journal of Medicine. 368(16):1489–1497. — DOI: 10.1056/NEJMoa1212722. — doi:10.1056/NEJMoa1212722
- Jaff S, Zeraattalab-Motlagh S, Amiri Khosroshahi R, et al. (2023). The effect of selenium therapy in critically ill patients: an umbrella review of systematic reviews and meta-analysis of randomized controlled trials. European Journal of Medical Research. 28(1):104. — DOI: 10.1186/s40001-023-01075-w. — doi:10.1186/s40001-023-01075-w
- Kupka R, Mugusi F, Aboud S, et al. (2009). Effect of selenium supplements on hemoglobin concentration and morbidity among HIV-1-infected Tanzanian women. Clinical Infectious Diseases. 48(10):1475–1478. — DOI: 10.1086/598334. — doi:10.1086/598334
- Rayman MP (2012). Selenium and human health. The Lancet. — DOI: 10.1016/S0140-6736(11)61452-9. — doi:10.1016/S0140-6736(11)61452-9
- Hoffmann PR, Berry MJ (2008). The influence of selenium on immune responses. Molecular Nutrition & Food Research. — DOI: 10.1002/mnfr.200700330. — doi:10.1002/mnfr.200700330
PubMed Topic Searches
Connections
- All Minerals
- Selenium Benefits Hub
- Selenium (Main Page)
- Selenium for Antioxidant Defense
- Selenium for Cancer Prevention
- Selenium and Thyroid Function
- Immune Boosting
- Glutathione
- Vitamin E
- Vitamin C
- Vitamin D3
- Zinc
- Cardiomyopathy (Keshan)
- Prostate Conditions
- Hashimoto's Thyroiditis
- Crohn's Disease
- Organ Meats
- Tuna
- Eggs
- Deficiency
- Toxicity
- History
- Sources